We are live on ! Find out more
AUPH icon

Aurinia Pharmaceuticals
AUPH

16 hedge funds and large institutions have $16.8M invested in Aurinia Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

33% more funds holding

Funds holding: 12 → 16 (+4)

17% less capital invested

Capital invested by funds: $20.1M → $16.8M (-$3.36M)

Holders
16
Holders Change
+4
Holders Change %
+33.33%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$101K
2
UBS Group
UBS Group
Switzerland
+$45.9K
3
RG
Redmile Group
California
+$45.1K
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$20.4K
5
TRCT
Tower Research Capital (TRC)
New York
+$19.5K

Top Sellers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
-$1.07M
2
CCMU
Cheyne Capital Management (UK)
United Kingdom
-$257K
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$527
4
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
-$3
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$6.29M – – –
GPP
2
Great Point Partners
Connecticut
$6.16M – – –
BBA
3
Baker Bros. Advisors
New York
$1.79M – – –
EAM
4
EverPoint Asset Management
Connecticut
$1.63M – – –
Millennium Management
5
Millennium Management
New York
$359K – – –
LOAMU
6
Lombard Odier Asset Management (USA)
New York
$284K +$12.5K +4,599 +4%
Renaissance Technologies
7
Renaissance Technologies
New York
$92K +$101K +37,200 New
UBS Group
8
UBS Group
Switzerland
$42K +$45.9K +16,910 New
RG
9
Redmile Group
California
$41K +$45.1K +16,610 New
Royal Bank of Canada
10
Royal Bank of Canada
Ontario, Canada
$27K -$527 -194 -2%
TRCT
11
Tower Research Capital (TRC)
New York
$19K +$19.5K +7,167 +1,195%
Bank of Montreal
12
Bank of Montreal
Ontario, Canada
$19K +$20.4K +7,500 New
Morgan Stanley
13
Morgan Stanley
New York
$2K +$149 +55 +6%
PAIM
14
Punch & Associates Investment Management
Minnesota
$741 +$815 +300 New
ACP
15
Acuta Capital Partners
California
– -$1.07M -377,427 Closed
CCMU
16
Cheyne Capital Management (UK)
United Kingdom
– -$257K -90,000 Closed
Toronto Dominion Bank
17
Toronto Dominion Bank
Ontario, Canada
– -$3 -1 -2%
Citigroup
18
Citigroup
New York
– +$16 +6 New

AUPH Hedge Fund Activity: Q4 2015 in Review

16 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2015, worth a combined $16.8M — down 17% from $20.1M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new AUPH positions and 2 closed out — a net gain of 4 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $101K. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $1.07M sold.

  • 16 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2015, up from 12 in Q3 2015.
  • Funds reported $16.8M of Aurinia Pharmaceuticals stock for Q4 2015, down 17% quarter-over-quarter.
  • 6 funds opened new Aurinia Pharmaceuticals positions in Q4 2015 and 2 closed out, a net change of +4 holders.
  • The largest Aurinia Pharmaceuticals buyer in Q4 2015 was Renaissance Technologies, an estimated $101K added.
  • The largest Aurinia Pharmaceuticals seller in Q4 2015 was Acuta Capital Partners, an estimated $1.07M sold.

Based on aggregated 13F filings for Q4 2015.